Smad4 is required to inhibit osteoclastogenesis and maintain bone mass
Mayu Morita(Keio University), Takeshi Miyamoto(Kumamoto Health Science University), Kana Miyamoto(Kumamoto University), Ryuichi Watanabe(Keio University), Masamichi Takami(Showa University), Tetsuro Yasui(Teikyo University), Masaya Nakamura(Keio University), Taneaki Nakagawa(Keio University), Akihiko Yoshimura(Keio University), Keiko Ozato(National Institutes of Health), Chu‐Xia Deng(Tongji University), Hiromasa Kawana, Sakae Tanaka(University of Tokyo Hospital), Tami Kobayashi(Keio University), Takatsugu Oike(Keio University), Morio Matsumoto(Keio University Hospital), Yoshiaki Toyama(Keio University), Ryotaro Iwasaki(Keio University), Hiroyuki Aburatani(The University of Tokyo), Yuiko Sato(Keio University), Shigeyuki Yoshida(Keio University)
Cited by 22
Related Papers
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
|Cell Metabolism|2006|771